Green Stone Swiss Co ., ltd.

Egalet, Teva sign agreement to commercialize SPRIX Na

Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd. ("Teva"), a leading global pharmaceutical company. With this agreement, Egalet granted Teva exclusive marketing and commercialization rights to SPRIX (ketorolac tromethamine) Nasal Spray in Israel, Gaza and the West Bank. Teva, a leader in the commercialization of central nervous system (CNS) products, including many in pain management, will be responsible for registering, marketing, distributing and selling SPRIX Nasal Spray in these territories. Under the terms of the agreement, Egalet will receive an undisclosed upfront payment, sales-based milestones and will share in the profits from net sales of SPRIX in these territories.
"This partnership showcases both companies' commitment to delivering effective, unique pain medicines and leverages the regional commercial expertise of Teva," said Bob Radie, president and chief executive officer of Egalet. "Our agreement with Teva represents a significant milestone for our company as it is our first distribution agreement outside the U.S. for SPRIX Nasal Spray and the first step to expanding the global reach of our commercial products. We will continue to seek out these types of collaborations so that we can deliver our novel treatment options to patients across the globe."
more about:Dapoxetine hydrochloride


Send inquiry online For more product information and  prices

Contact UsAfter sending the online inquiry, we will reply you as soon as possible, if not get any response on time please contact us by Tel or Email. —— Green Stone Swiss
1. Email: sales@raw-pharmaceutical-materials.com(Pharmaceutical Ingredients Manufacturer & Supplier & Exporter.)
2. Tel: +86 592 5365887
3. WhatsApp: +86 189 6515 7632
4. Send inquiry online::